Should I Buy CELC? CELC 2026 Analysis

Should You Buy Celcuity Inc (CELC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

106.750

1 Day change

2.37%

52 Week Range

120.310

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: near-term technicals have weakened (negative, expanding MACD histogram) and price is trading below the key pivot (111.708).
No Intellectia edge today: AI Stock Picker = no signal; SwingMax = no recent signal (so there’s no proprietary “must-buy” trigger overriding other factors).
Sentiment is mixed: Wall Street is broadly constructive, but insider selling has surged (+657.10% last month), which is a notable near-term overhang.
If you must act immediately, risk/reward is not compelling at 107.5 with nearby support at ~105.1 and overhead resistance back at the pivot/118 area; better odds typically come after reclaiming the pivot or a cleaner bounce off support.

Technical Analysis

Price/levels: Pre-market ~107.52, below Pivot 111.708; sitting above S1 105.093 (near-term support) with resistance at 111.708 then R1 118.322.
Trend: Moving averages are bullishly stacked (SMA_5 > SMA_20 > SMA_200), implying the larger trend remains up, but the current move looks like a pullback within that uptrend.
Momentum: MACD histogram -0.587 and negatively expanding = bearish momentum building short-term.
RSI: RSI_6 ~39.2 = weak/leaning bearish (not oversold), suggesting downside room remains before a typical “washed-out” bounce.
Pattern-projection (provided): modest upside bias longer than 1 day (next month +2.1%) but not strong enough to offset current short-term momentum weakness for an immediate entry.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning: Very low open-interest put/call (0.17) looks bullish/low-hedge, but today’s volume put/call (1.3) leans bearish (more puts trading than calls).
Activity: Today’s options volume is very light (99 vs 5D/10D avgs ~1564/1913), so the volume signal may be noisy.
Volatility: 30D IV ~72.77 vs historical vol ~50.21 (options pricing a premium), while IV rank ~6.43 / IV percentile ~31 suggests IV is not extreme versus its own recent history.
Net read: Sentiment mixed-to-slightly-cautious near term (bearish volume skew) with structurally low put OI.

Technical Summary

Sell

Buy

Positive Catalysts

- Clinical/regulatory catalysts: upcoming VIKTORIA-1 PIK3CA-mutant cohort readout expected Q1–Q2 2026; NDA for PIK3CA-wt referenced as on track (per prior analyst notes).
- Street narrative: multiple recent bullish initiations/raised targets (Wells Fargo, Wolfe, Stifel, Craig-Hallum) and “acquisition opportunity” framing could support dips.
- Trend context: longer-term uptrend remains intact via bullish moving-average stack, even as momentum cools short-term.
- Hedge fund stance: neutral (no strong negative flow signal from that cohort in the provided data).

Neutral/Negative Catalysts

- Insider activity: insiders are selling, with selling amount up 657.10% over the last month—often a near-term sentiment/overhang signal.
- Technical deterioration: bearish/expanding MACD and price below pivot increases the odds of a retest of support (~105, then ~101).
- Valuation/expectations risk: one major bearish counterpoint—H.C. Wainwright downgrade to Neutral citing “priced for perfection” after a massive run.
- Fundamentals: still pre-revenue (Q3 revenue 0), so the stock is highly catalyst-dependent (binary biotech-style risk).
- News flow provided is not CELC-specific (focuses on Xpeng/EV and broad futures), offering no direct positive catalyst for CELC in the immediate tape.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (0.00% YoY) — still pre-commercial/no top-line contribution.
Profitability: Net loss improved to -$43.804M (47.03% YoY improvement), indicating better cost control/operating leverage vs prior year.
EPS: improved to -0.92 (31.43% YoY improvement), but still meaningfully negative.
Takeaway: improving loss profile, but the equity story remains primarily driven by upcoming trial/regulatory milestones rather than current operating revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: predominantly bullish coverage actions with multiple initiations/target raises in Nov–Dec 2025, offset by one notable downgrade.
Bull case (Wall St pros):
- Wells Fargo: Overweight, PT $126; sees VIKTORIA-1 mutant readout as largely de-risked and views current price as not reflecting gedatolisib opportunity.
- Wolfe: Outperform, PT $110; highlights Phase 3 win momentum and frames CELC as a potential top-tier M&A target.
- Stifel: Buy, PT raised to $115; increased sales/odds estimates.
- Craig-Hallum: Buy, PT raised to $108; emphasizes NDA timing and upcoming mutant readout.
Bear case (Wall St cons):
- H.C. Wainwright: downgraded to Neutral, PT $94; argues shares are “priced for perfection” after extreme appreciation, implying asymmetric downside if execution/catalysts disappoint.
Net: Wall Street skews positive on the platform/catalysts, but the key pushback is valuation/expectations risk at current levels.

9 Analyst Rating

Wall Street analysts forecast CELC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 106.5 USD with a low forecast of 94 USD and a high forecast of 126 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 104.280

Low

Averages

106.5

High

126

Current: 104.280

Low

Averages

106.5

High

126

Wells Fargo

initiated

$126

AI Analysis

2025-12-12

Reason

Wells Fargo

Price Target

$126

AI Analysis

2025-12-12

initiated

Reason

As previously reported, Wells Fargo initiated coverage of Celcuity with an Overweight rating and $126 price target. The firm believes the upcoming VIKTORIA-1 PI3KCA mutant readout is largely de-risked by the wild-type readout and Phase 1. The current stock price doesn't reflect gedatolisib's market opportunity in breast cancer and metastatic castration-resistant prostate cancer is a free call option at these levels, Wells adds.

Wells Fargo

initiated

$126

2025-12-12

Reason

Wells Fargo

Price Target

$126

2025-12-12

initiated

Reason

Wells Fargo initiated coverage of Celcuity with an Overweight rating and $126 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CELC

Unlock Now

CELC Should I Buy

CELC Should I Buy

Should You Buy Celcuity Inc (CELC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch